Literature DB >> 33741015

Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy?

Colin S Hill1, Sarah Han-Oh2, Zhi Cheng2, Ken Kang-Hsin Wang2, Jeffrey J Meyer2, Joseph M Herman3, Amol K Narang2.   

Abstract

PURPOSE: Variation in target positioning represents a challenge to set-up reproducibility and reliability of dose delivery with stereotactic body radiation therapy (SBRT) for pancreatic adenocarcinoma (PDAC). While on-board imaging for fiducial matching allows for daily shifts to optimize target positioning, the magnitude of the shift as a result of inter- and intra-fraction variation may directly impact target coverage and dose to organs-at-risk. Herein, we characterize the variation patterns for PDAC patients treated at a high-volume institution with SBRT.
METHODS: We reviewed 30 consecutive patients who received SBRT using active breathing coordination (ABC). Patients were aligned to bone and then subsequently shifted to fiducials. Inter-fraction and intra-fraction scans were reviewed to quantify the mean and maximum shift along each axis, and the shift magnitude. A linear regression model was conducted to investigate the relationship between the inter- and intra-fraction shifts.
RESULTS: The mean inter-fraction shift in the LR, AP, and SI axes was 3.1 ± 1.8 mm, 2.9 ± 1.7 mm, and 3.5 ± 2.2 mm, respectively, and the mean vector shift was 6.4 ± 2.3 mm. The mean intra-fraction shift in the LR, AP, and SI directions were 2.0 ± 0.9 mm, 2.0 ± 1.3 mm, and 2.3 ± 1.4 mm, respectively, and the mean vector shift was 4.3 ± 1.8 mm. A linear regression model showed a significant relationship between the inter- and intra-fraction shift in the AP and SI axis and the shift magnitude.
CONCLUSIONS: Clinically significant inter- and intra-fraction variation occurs during treatment of PDAC with SBRT even with a comprehensive motion management strategy that utilizes ABC. Future studies to investigate how these variations could lead to variation in the dose to the target and OAR should be investigated. Strategies to mitigate the dosimetric impact, including real time imaging and adaptive therapy, in select cases should be considered.

Entities:  

Keywords:  Active breathing coordination; Motion management; PTV design; Pancreatic adenocarcinoma; SBRT

Mesh:

Year:  2021        PMID: 33741015      PMCID: PMC7980583          DOI: 10.1186/s13014-021-01782-w

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


  35 in total

1.  The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy.

Authors:  M van Herk; P Remeijer; C Rasch; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-01       Impact factor: 7.038

2.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

3.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

4.  Does the pancreas move with respiration?

Authors:  Deepak Kumar Bhasin; Surinder Singh Rana; Sujeet Jahagirdar; Birinder Nagi
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

5.  Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer.

Authors:  Nancy El-Bared; Lorraine Portelance; Benjamin O Spieler; Deukwoo Kwon; Kyle R Padgett; Karen M Brown; Eric A Mellon
Journal:  Pract Radiat Oncol       Date:  2018-08-25

6.  Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.

Authors:  D J Klaassen; J M MacIntyre; G E Catton; P F Engstrom; C G Moertel
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

7.  Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer.

Authors:  Barbara Bussels; Laurence Goethals; Michel Feron; Didier Bielen; Steven Dymarkowski; Paul Suetens; Karin Haustermans
Journal:  Radiother Oncol       Date:  2003-07       Impact factor: 6.280

8.  Adequacy of inhale/exhale breathhold CT based ITV margins and image-guided registration for free-breathing pancreas and liver SBRT.

Authors:  Wensha Yang; Benedick A Fraass; Robert Reznik; Nicholas Nissen; Simon Lo; Laith H Jamil; Kapil Gupta; Howard Sandler; Richard Tuli
Journal:  Radiat Oncol       Date:  2014-01-09       Impact factor: 3.481

9.  Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer.

Authors:  Soumon Rudra; Naomi Jiang; Stephen A Rosenberg; Jeffrey R Olsen; Michael C Roach; Leping Wan; Lorraine Portelance; Eric A Mellon; Anna Bruynzeel; Frank Lagerwaard; Michael F Bassetti; Parag J Parikh; Percy P Lee
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452

Review 10.  Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls.

Authors:  Luca Boldrini; Davide Cusumano; Francesco Cellini; Luigi Azario; Gian Carlo Mattiucci; Vincenzo Valentini
Journal:  Radiat Oncol       Date:  2019-04-29       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.